| US 7,452,982 B2 | ||
| Immunogenic complex | ||
| Nils Lycke, Savedalen (Sweden); Kristian Dalsgaard, Kalvehave (Denmark); Allan Mc Mowat, Glasgow (United Kingdom); Bjorn Lowenadler, Askim (Sweden); and Peter Kaastrup, Maaloev (Denmark) | ||
| Assigned to Arexis AB, Molndal (Sweden) | ||
| Appl. No. 10/381,882 PCT Filed Oct. 01, 2001, PCT No. PCT/SE01/02117 § 371(c)(1), (2), (4) Date Aug. 19, 2003, PCT Pub. No. WO02/26255, PCT Pub. Date Apr. 04, 2002. |
||
| Claims priority of application No. 0003538 (SE), filed on Sep. 29, 2000. | ||
| Prior Publication US 2004/0052815 A1, Mar. 18, 2004 | ||
| Int. Cl. C07K 1/00 (2006.01); C07K 14/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C08H 1/00 (2006.01); A61K 39/385 (2006.01); A61K 45/00 (2006.01) | ||
| U.S. Cl. 530—403 [530/350; 424/282.1; 424/197.11] | 13 Claims |
| 1. An immunogenic complex comprising:
at least one glycoside and at least one lipid, integrated into an iscom complex or matrix;
at least one antigen integrated into the iscom complex or coupled onto or mixed with the iscom complex or iscom matrix complex;
and
an adjuvant comprising
(i) an isolated subunit of an A1 subunit of a bacterial enterotoxin selected from the group consisting of cholera toxin and
E. coli heat labile enterotoxin, and
(ii) a fragment of protein A comprising the D region of protein A, said fragment having the ability to bind to Ig or Fc receptors
on an antigen-presenting cell.
|